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There is a  close relationship between  the response of mononuclear phagocytes to 
bacterial infections and their capacity to inhibit tumor growth. Macrophages obtained 
from mice infected with Listeria monocytogenes or with Bacillus Calmette-Gu~rin show 
enhanced  bactericidal  activity;  in  addition,  these  cells  are  reported  to  inhibit  the 
growth of tumors in vivo (1, 2) and destroy tumor cells in vitro (3-5). These findings 
suggest  that  mononuclear  phagocytes  have  the  capacity  to  play  a  pivotal  role  in 
defending the host against neoplasms. 
To date, however, most of the systems in which macrophage cytotoxicity has been 
examined have involved incubation of the effector cells with the tumor cell targets in 
vitro.  Cytotoxicity  has  generally  been  assessed  by  release  of  a  radioactive  label 
previously incorporated  into the target cell or by a  measurement of the number of 
viable tumor cells remaining at the end of the assay. However, there is no quantitative 
standard by which cytotoxic effects in vitro can be correlated with inhibition of tumor 
growth in vivo. Numerous studies have described the destruction  in vitro of 60-70% 
of an  inoculum  of tumor  cells  by  suitably  activated  macrophages  (6,  7).  Yet,  if 
activated macrophages are to make a  meaningful contribution  to the eradication of 
neoplasms, the macrophages must be capable of destroying the clonogenic tumor cells 
within a tumor bed in the tumor-bearing host. 
To evaluate the efficacy of mononuclear phagocytes in tumor resistance, we have 
examined the capacity of these cells to inhibit the formation of tumors by B559 cells, 
a subclone of the B 16 melanoma (8, 9), in its syngeneic host, the C57BL/6 mouse. We 
have chosen this system for several reasons. The B16 melanoma arose spontaneously. 
Like most spontaneously arising tumors it is not immunogenic (as assayed in challenge- 
protection  experiments)  and  does  not  elicit  concomitant  immunity  (Results).  The 
tumor has been extensively studied, grows rapidly to form lethal tumors in vivo, and 
is easy to propagate and to clone in vitro. The experiments described below examine 
the tumorigenic  potential  of B559  cells when  these cells are injected  into syngeneic 
mice together with various putative cytotoxic cells. 
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Materials and Methods 
Tumor Cells.  Bs59  cells, a subclone  of the B 16 melanoma, have been extensively  characterized 
(8, 9). The cells were maintained in monolayer culture in modified Eagle's medium (MEM) 1 
(Grand Island Biological Co., Grand Island, N. Y.) supplemented with 7.5% fetal bovine serum 
in a humidified atmosphere containing 6% CO2. Before their use, a semiconfluent monolayer 
was disaggregated with 0.25% trypsin and EDTA (Grand Island Biological Co.) for 5 rain. The 
cells were then washed twice with phosphate-buffered saline without Ca  ++ or Mg  ÷+ (PBS), and 
then resuspended in PBS. 
Mice.  Female C57BL/6J mice, between 6 and 8 wk of age, were obtained from The Jackson 
Laboratory (Bar Harbor, Maine). These animals were  used either as  tumor recipients or as 
donors of peritoneal cells. For experiments requiring irradiation, mice were exposed  to 650 rad 
from a 2,400-Ci cesium source gamma cell (located at the Sloan-Kettering  Institute for Cancer 
Research, New York).  BALB/c nude mice were  a generous gift of Dr. Seung-II Shin (Albert 
Einstein College of Medicine, Bronx, N. Y.). (C57BL/6 X BALB/c)F1 mice, 8 wk of age, were 
purchased from The Jackson Laboratory. 
BCG.  Mycobacterium  boris,  strain  Bacillus Calmette-Gu~rin (BCG)  (Pasteur  A1011)  was 
obtained frozen  from  the  Trudeau  Institute (Saranac  Lake,  N.  Y.);  and was  used  for  all 
experiments. The mice were  injected either intravenously or intraperitoneally with  10  v orga- 
nisms in 0.1 ml of PBS. 21-24 d later, the mice were injected with an equal number of either 
live or dead BCG intraperitoneally, and the peritoneal exudate was harvested 3-4 d later. For 
experiments in which BCG-immunized mice were  challenged with the melanoma, the mice 
were immunized with BCG according to the same protocol. 3-4 d after the second intraperi- 
toneal injection of BCG, the mice were  inoculated either subcutaneously or intraperitoneally 
with B.~59 cells. For injection with dead BCG, the vials were  autoclaved at a  temperature of 
120°C  at a pressure of 15 Ib/in  2 for 25 min, and then diluted to  10  v organisms/0.1 ml. The 
peritoneal exudate from mice injected twice with heat-killed BCG contained an average of 35- 
45% macrophages as determined by Wright-Giemsa staining. 
Peritoneal Cells 
Peritoneal cells were harvested and maintained in culture by a modification of the method 
of Cohn and Benson (10) as described by Michl et al. (11). 
INFLAMMATORY EXUDATE  CELLS.  For some experiments, mice were injected intraperitoneally 
with  1 ml of brewer's thioglycollate medium (Difco  Laboratories, Detroit, Mich.),  1 or 4 d 
before harvest of the peritoneal exudate. Wright-Giemsa staining  of cytoeentrifuge preparations 
revealed a differential count of >80% macrophages 4 d after thioglycollate injection, and ~80- 
90%  polymorphonuclear leukocytes  when  the  peritoneal exudate  was  harvested  1 d  after 
intraperitoneal thioglyeollate injection. 
BCG-ELICITED PERITONEAL CELLS.  After immunization with heat-killed BCG according to 
the  schedule  outlined above,  the  peritoneal  cells  were  harvested  as  described.  For  some 
experiments, the  adherent  peritoneal cells  were  separated  from  the  nonadherent cells  by 
7  7  incubating 2  ×  l0-3  ×  l0  peritoneal cells  on  100-mm  glass  Petri  dishes  in MEM  that 
contained 20% fetal bovine serum for 3-4 h at 370C in a humidified CO2 incubator. The plates 
were  then washed three times with ~5 ml of ice-cold  PBS that contained 1 mM EDTA. To 
obtain the nonadherent cell fraction, these wash fluids were combined and centrifuged at  150 
g' for 10 min at 4°C. The cell pellet was resuspended in PBS and stored at 4"C until used. The 
adherent-cell fraction was harvested by incubating the cells remaining on the surface of each 
glass Petri dish in 5 mi of PBS that contained 1 mM EDTA for 10 rain at 4°C. The cells were 
then  gently scraped  off with  a  sterile  rubber policeman, centrifuged, and  resuspended as 
described  above  for  the  nonadherent cells.  Generally, ~50%  of the  total  cells  plated  were 
recovered  in the  nonadherent cell  fraction;  the  viability of these  cells  was  usually ~80%. 
Recovery of adherent cells averaged between 30 and 50% of the total cells plated; their viability, 
i Abbreviations  used in thz~ paper: BCG, Mycobacterium  boris, strain Bacillus Calmette-Gu~rin; BCG-PE, BCG- 
elicited peritoneal exudate cells; HRP-IgG, horseradish peroxidase-anti horseradish peroxidase immune 
complexes; IgG-GRBC, IgG-coated, glutaraldehyde-fixed sheep erythrocytes; PBS, phosphate-buffered 
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as determined by trypan blue exclusion, was usually >70%. In all experiments, the cell number 
reported is the number of viable cells. 
Tumor Neutralization Assay.  A modification of the tumor neutralization  assay developed by 
Winn (12) was used to assess the effectiveness  of various peritoneal exudate cells against B.~59 
melanoma cells in vivo. Peritoneal cells were harvested as described above, washed, resuspended 
in PBS, and then mixed at various cell concentrations with B.~59 cells. A final vol of 0.2 ml of 
the cell mixture was then injected either subcutaneously in the flank or intraperitoneally into 
C57BL/6J mice. Mice were monitored twice-weekly for tumor formation. At the end of each 
experiment, mice without gross evidence of tumors were killed and dissected.  The time of killing 
of these mice is indicated in the Figure and Table legends.  In all  experiments,  the number of 
mice injected is the number reported. No mice used in any experiment were excluded from the 
data reported. 
Phagocytosis Assays.  Binding and phagocytosis of IgG- or complement-coated sheep eryth- 
rocytes was measured as described previously (11). The phagocytic index was determined by 
multiplying  the  percentage  of macrophages  that  had  ingested  erythrocytes by the  average 
number of erythrocytes ingested per macrophage; the binding index was obtained similarly. 
Uptake of horseradish peroxidase-anti-horseradish  peroxidase immune complexes was carried 
out according to the method of Steinman and Cohn (13). Phagocytosis of IgG-coated glutar- 
aldehyde-fixed sheep erythrocytes was assayed by fluorescence microscopy (J. D. Loike and S. 
C. Silverstein.  Manuscript in preparation.). 
Results 
Several  protocols  for  eliciting  tumoricidal  macrophages  with  BCG  have  been 
described  (1,  4-6).  In  most  of these  reports,  living  bacteria  were  injected  into  the 
mice.  To  determine  whether  an  infection  with  living  BCG  was  necessary  for  the 
development  of cytotoxic peritoneal  cells,  we carried  out  the  following experiment. 
Mice were injected intravenously with live BCG to establish a Mycobacterium infection 
(assayed by a  two- to five-fold increase  in spleen  weight over normal spleen  weights 
at autopsy), and then boosted intraperitoneally  14-21  d  later with either live or dead 
(heat-killed)  BCG. Other groups of mice received an initial  intraperitoneal  injection 
of dead BCG followed by a  boost with dead BCG. The peritoneal  exudate cells from 
animals  treated  in  these  ways were harvested,  mixed  with  the  melanoma  cells,  and 
then injected subcutaneously into the flank of normal C57BL/6 mice. The results of 
these experiments are presented in Fig.  1. Although the peritoneal cells elicited by live 
plus live BCG, and live plus dead BCG inhibited  tumor engraftment by 60 and 25%, 
respectively,  only the  peritoneal  cells  elicited  by two  injections  of dead  BCG  were 
100%  successful  in  preventing  tumorigenesis  by  the  melanoma.  Additional  experi- 
ments showed that peritoneal cells from mice injected intraperitoneally  with a  single 
dose of live  BCG  24  d  before harvest,  or with  heat-killed  BCG 4  d  before harvest, 
failed  to inhibit  melanoma  formation  (data  not shown).  These  results  indicate  that 
systemic Mycobacterium infection is not a  prerequisite  for the development  of tumori- 
cidal  peritoneal  cells.  In  fact,  systemic  infection  is  relatively  inefficient,  whereas 
immunization  with  two  inoculations  of dead  BCG  intraperitoneally  is  the  most 
efficacious of the six protocols tested.  Therefore in all subsequent  experiments,  mice 
that  had received two injections of dead BCG according to the protocol described in 
Materials  and Methods were used as donors of peritoneal  cells. 
To  determine  whether  BCG  immunization  confers  systemic  immunity  to  B~59 
melanoma cells,  mice were immunized  with  dead  BCG,  and  then  injected  with  the 
melanoma cells either subcutaneously or intraperitoneally.  The results of a represent- 
ative experiment  are presented  in Table I. As can be seen from the data, when BCG 660  PREVENTION  OF  MELANOMA  GRAFTS  BY  ACTIVATED  MACROPHAGES 
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FIG.  1.  G57BL/6J mice were injected either intravenously with 107 living BCG organisms in 0.1 
ml of PBS or intraperitoneally with 10  v heat-killed BCG organisms in 0.1 ml PBS. 21-24 d later, the 
mice  were  injected  intraperitoneally with  l0  T live or  dead  BGG.  The  peritoneal  exudate  was 
harvested 3-4 d later, mixed with the B~59 melanoma cells at a ratio of peritoneal cells:melanoma 
cells of 20:1,  and the mixture was injected subcutaneously into naive C57BL/6J mice. The mice 
were monitored twice-weekly  for tumor formation. 50 d  after inoculation of melanoma cells,  the 
mice were killed and dissected.  The data are the average of two experiments. At least five mice were 
used in each group in each experiment. 
TABLE  I 
Effects of lntraperitoneal BCG Immunization on Tumorigenicity ofB659 
Melanoma Cells 
No. mice with tu- 
Route of injection of Bs59 cells*  mors/No, mice in-  Latency 
jected 
d 
Intraperitoneal  0/15  --:~ 
Subcutaneous  9/9  17-21 
* 2  x  105  Bs59  melanoma  cells  were  injected  either  intraperitoneally or 
subcutaneously into syngeneic mice immunized with dead BCG as described 
in Materials and Methods. Control experiments showed that this tumor cell 
dose results in tumors in  100% of the naive (non-BGG-immunized) mice 
injected, with a latent period of 12-16 d. 
:~ 35 d after inoculation, the mice were killed and dissected. 
immunization  was intraperitoneal,  and  the tumor  challenge was also intraperitoneal, 
100% of the mice were  protected  from the tumor.  However,  when  mice were  immu- 
nized  intraperitoneally  with  BCG  and  challenged  with  tumor  cells subcutaneously, 
all of the mice succumbed  to the melanoma,  despite the presence in their peritoneal 
cavities of cells capable  of eliminating  the tumor. 
To  determine  whether  the  BCG-induced  protection  was  absolute  or  if  it  was 
dependent  upon  the number  of melanoma  cells injected,  control  and  BCG-immune V.  FREEDMAN,  T.  CALVELLI,  S.  SILAGI,  AND  S.  SILVERSTEIN  661 
animals were inoculated  intraperitoneally with varying numbers of B559  cells. At a 
tumor cell  inoculum  of  105, 2  X  105, or  5  X  l0  s  cells,  100%  of the  unimmunized 
animals developed tumors. In contrast, when the same number of cells was inoculated 
intraperitoneally  into  the  BCG-immune animals,  tumor  formation was completely 
inhibited  (Fig. 2). The complete absence of tumors was shown by dissection of these 
mice 60 d  after injection  with  the tumor cells.  However, when  106  melanoma cells 
were injected intraperitoneally into the BCG-immunized mice, ~20% of the animals, 
upon  dissection,  showed  a  peppering of the  peritoneal  cavity with  tumor  nodules. 
Furthermore, when 5  ×  106 melanoma cells were injected intraperitoneally,  100% of 
the mice developed tumors at this site. These results indicate that although the BCG- 
immune mouse is protected against 5- to  10-fold the  100% tumorigenic dose of B559 
cells, a  50-fold-excess number of tumor cells can override this protection. 
The results in Table I further suggest that although BCG-immune animals contain 
tumoridical cells in their peritoneal cavities, these cells are not present and/or cannot 
be  delivered  to  other  sites,  such  as  the  subcutaneous  tissues,  when  B559  cells  are 
inoculated at these distant sites. To examine this issue further, and to determine the 
minimal  number  of  BCG-immune  peritoneal  cells  required  to  protect  against  a 
subcutaneous  challenge  with  B559  cells,  we  mixed  varying numbers  of peritoneal 
exudate cells from BCG-immunized mice with a  constant  number (2  X  105) of B559 
cells and inoculated them subcutaneously into naive C57BL/6J mice. Control exper- 
iments showed  that  2  ×  105  B~59 cells was a  100%  tumorigenic dose in  these mice. 
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FIG.  2.  C57BL/6J  mice were primed and boosted with  l0  7 heat-killed BCG intraperitoneally as 
described in Materials and Methods. 4 d after the last injection of BCG, the mice were challenged 
intraperitoneally with varying numbers of B559 melanoma cells and then monitored twice weekly 
for tumor development. Mice were considered tumor free only when no melanoma nodules were 
observed intraperitoneally upon dissection at 60 d after the melanoma challenge. 662  PREVENTION OF  MELANOMA GRAFTS  BY ACTIVATED  MACROPIfAGES 
Mice  injected  with  2  ×  l0  s  Bs59  cells  and  an  equal  number  of  BCG-immune 
peritoneal  cells  all  developed  tumors.  However,  mice  inoculated  with  the  same 
number of B559 cells and a  20-fold or greater excess of BCG immune peritoneal  cells 
did  not  develop tumors  (Fig.  3),  whereas  mice inoculated  with  Bs59 cells  and  a  10- 
fold excess  of BCG-immune  peritoneal  cells  exhibited  a  delay  in  tumor  formation. 
Nevertheless,  80%  of  the  mice  in  this  last  group  ultimately  succumbed  to  the 
melanoma.  Because the number of cells in the BCG-immune peritoneal  cavity is ~5 
×  10  ~,  these  results  suggest  that  roughly the same  number of BCG-immune cells  is 
required  to protect subcutaneously as is required  to protect intraperitoneally. 
To  determine  whether  inhibition  of tumor  engraftment  could  be  produced  by 
leukocytes induced by inflammatory stimuli other than BCG, we mixed 2 ×  105 Bs59 
cells with 5 ×  106 peritoneal cells from mice injected 4 d previously with thioglycollate 
broth and injected this mixture subcutaneously into C57BL/6J mice. In this case, the 
peritoneal  exudate  consisted  of 80-90%  macrophages  by  Wright-Giemsa  staining. 
These  mice  all  developed  melanomas  at  the  site  of injection  (Table  II).  We  had 
previously  noted  that  peritoneal  cells  from  BCG-immunized  mice  contain  6-15% 
polymorphonuclear leukocytes  (by Wright-Giemsa staining).  To determine  whether 
polymorphonuclear leukocytes could inhibit melanoma formation, peritoneal exudate 
cells  (>90% of which were polymorphonuclear leukocytes) were obtained  from mice 
injected  1 d  previously with thioglycollate medium.  Mice inoculated with a  mixture 
of these exudate cells and Bs59 cells all developed tumors  (Table  II). Similar  results 
were obtained when resident peritoneal cells (which are ~30-40% macrophages) were 
injected together with Bs59 cells (Table II). These findings demonstrate that resident 
macrophages, thioglycollate-elicited macrophages, and polymorphonuclear leukocytes 
are incapable of inhibiting tumor formation when mixed with Bs59 cells. The failure 
of polymorphonuclear leukocytes to inhibit tumor formation is especially noteworthy, 
because Nathan et al.  (14)  have shown that when these cells are stimulated  pharma- 
0 
E 
E 
t~ 
8G 
60 
40 
I 
20L 
,% 
%,  ,% 
,% 
% 
% 
\ 
% l 
\ 
\ 
\ 
\ 
\ 
\ 
\ 
\ 
\ 
\ 
\ 
\ \ 
3  5  t0  20  30 
Ratio of BCG-elicited peritoneal exudate cells: melanoma cells 
Fie.  3.  Bs59 melanoma  cells (2  X  10  r')  were mixed with  varying numbers  of BCG-induced 
peritoneal cells and injected subcutaneously into syngeneic mice. The mice were monitored twice 
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TAm.~  II 
Resident and Thioglycollate-Broth-elicited  Peritoneal Cells Do Not Suppress Tumorigenicity of B559 
Melanoma Cells 
Source of peritoneal cells* 
No. mice 
with 
tumors/No. 
mice in- 
jected 
Latency* 
BCG-immunized mice 
ThioglycoUate-injected mice 
1 d (80-90% polymorphonuclear leukocytes) 
4 d (80% macrophages) 
Resident (uninjected) 
Control: B559 cells alone 
d 
1/30  40 
10/10  8-10 
25/25  12-16 
18/19  16-20 
20/20  10-14 
* The peritoneal cells were elicited from C57BL/6J  mice as described in Materials and Methods. Heat- 
killed BCG was used for immunization. In each case, naive C57BL/6J mice were inoculated subcutane- 
ously with the cell mixture that consisted of 2 ×  105 B559 cells and 5 ×  10  e peritoneal cells. 
:[: Latency =  the number of days before the tumor nodule is palpable. Mice without gross evidence of 
tumors 60 d after inoculation were killed and dissected. 
cologically, they do have the capacity to secret copious amounts of H202 and, thereby, 
destroy"some tumor cells. 
The data presented above, therefore, demonstrate that only the peritoneal exudate 
induced by BCG has tumoricidal activity when tested in vivo. Because the peritoneal 
cells from BCG-immunized mice were harvested 3-4 d after the second intraperitoneal 
injection  of dead  bacteria  (Materials  and  Methods),  it  was possible that  some dead 
bacteria  remained  in  the  peritoneal  exudate.  There have been  many reports  of the 
efficacy of live  BCG  introduced  intralesionally  to  induce  regression  of established 
tumors  (15,  16).  Therefore, to determine whether dead bacteria were responsible  for 
the abrogation of tumorigenicity in these experiments, the BCG-containing peritoneal 
cells  were  sonicated  in  a  Heat  Systems  sonicator  (Heat  Systems-Ultrasonics,  Inc., 
Plainview,  N.  Y.)  to release  their  content  of BCG  before admixture  with  the  B559 
cells, and the entire mixture was then injected subcutaneously into normal C57BL/6J 
mice. As Table III shows, only viable BCG-elicited cells are capable of preventing the 
engraftment  of the  melanoma.  In other experiments  (data  not  shown),  injection  of 
dead  BCG  into  B559  melanomas  growing  in  unimmunized  animals  did  not  cause 
either rejection or regression of the tumor,  further strengthening the conclusion that 
dead bacilli in the peritoneal cells do not themselves inhibit tumor engraftment. 
In the  modified  Winn-type assays described  above,  two  distinct  cell  populations 
were mixed together and inoculated into normal  hosts. Although the recipient  mice 
were  always  syngeneic  with  both  the  B559  melanoma  cells  and  the  BCG-elicited 
peritoneal  cells,  there  was  the  possibility  that  the  BCG-elicited  peritoneal  cells 
stimulated  the production of cytotoxic effector cells of recipient  origin and that  the 
melanoma cells were destroyed as bystanders to a host versus graft reaction. That the 
cytotoxicity and prevention of tumorigenicity  is not a  result  of a  bystander effect is 
shown by experiments  in which 5  ×  106 resident  peritoneal cells from unimmunized 
(C57BL/6J [H-2  b] ×  BALB/c [H-2d])Fa mice were mixed together with the melanoma 
cells before their subcutaneous  injection  into C57BL/6J mice.  9 of the  10 mice thus 664  PREVENTION  OF  MELANOMA  GRAFTS  BY  ACTIVATED  MACROPItAGES 
TABLE  III 
Requirement for Viable Peritoneal Cells in the Modified Winn Assay 
BCG-elicited peritoneal cells*  Cell viability:~  No. mice with tumors/ 
No. mice injected 
% 
Untreated  90  0/2011 
Sonicated§  0  19/20 
* Peritoneal cells were obtained from mice immunized twice with heat-killed 
BCG as described in Materials and Methods. 5 ×  106 viable BCG-elieited 
peritoneal cells  or the sonicated debris from 5  ×  106 BCG-peritoneal cell 
equivalents (determined by protein assay)  were  mixed with 2  ×  10  s B~59 
cells and injected subcutaneously into naive C57BL/6J mice. 
:~ Cell viability was determined microscopically by trypan blue exclusion. The 
sonicates were used only when no whole cells were observed on microscopic 
examination. 
§ Peritoneal cells were suspended in PBS at a  concentration of 5 X  107/ml, 
kept on ice, and subjected to three 10-s bursts in a Heat Systems sonicator. 
[I Mice without gross evidence of tumors 60 d after inoculation were killed and 
dissected. 
TABLE  IV 
Effect of Adherent and Nonadherent BCG-elicited Peritoneal Cells on Tumor 
Formation by B559 Cells 
No. mice with 
BCG-elicited peritoneal cells*  tumors/No. 
mice injected 
Total peritoneal cells +  B~59 cells 
• B559 cells alone 
NON-AD peritoneal cells +  B559 cells 
AD peritoneal cells +  Bs59 cells 
NON-AD +  AD +  Bs59 
1/30 
20/20 
8/9 
3/15 
0/4 
BCG-elicited peritoneal cells were obtained as described in Tables II and III. 
The cells were separated into adherent (AD)  and nonadherent (NON-AD) 
fractions by plating them on glass Petri dishes, as described in Materials and 
Methods. The cells were recovered and 5 X l0  s viable cells of each type was 
mixed with 2 ×  10  s B559 cells and injected subcutaneously into C57BL/6J 
mice.  Mice without evidence of tumors 60 d  after inoculation were killed 
and dissected. 
inoculated  developed  melanomas  at  the  site  of  injection,  despite  the  presence  of 
allogeneic cells in the nascent tumor  bed. 
To  identify  the  cell  type(s)  that  inhibit  melanoma  engraftment,  BCG-elicited 
peritoneal  cells  were  separated  into  adherent  and  nonadherent  subsets  by  plating 
them  for 4  h  on  glass  Petri  dishes  (Materials  and  Methods),  Approximately  40%  of 
these cells adhere  to the dishes. The  glass-adherent and nonadherent  cell populations 
were collected separately, mixed with the melanoma  cells, and injected subcutaneously 
into  C57BL/6J  mice,  80%  of  the  mice  that  received  adherent  BCG-elicited  cells 
together with melanoma  cells were protected  from  tumor  formation,  whereas 88% of 
the  mice  inoculated  with  a  mixture  of  nonadherent  BCG-elicited  cells  and  the 
melanoma  cells developed  tumors  (Table IV),  and  died.  The  latent period of tumor 
appearance  in  the  latter  group  was  slightly  longer  than  in  animals  inoculated  with 
melanoma  cells alone. In addition, in a  reconstitution experiment,  mice injected with V.  FREEDMAN, T. CALVELLI, S.  SILAGI, AND S.  SILVERSTEIN  665 
a mixture of melanoma cells and 2.5 ×  106 cells each of the adherent and nonadherent 
cell fractions were completely protected against tumor formation. 
Examination of  this  BCG-adherent  cell  fraction  by  phase-contrast  microscopy 
indicated that  the  majority of these cells were  macrophage-like in appearance. To 
further characterize these cells, we examined their expression of Fc and complement 
receptors  and  their capacity to  phagocytize a  variety of particles.  As  indicated in 
Table V, glass-adherent cells from the peritoneal cavities of normal or BCG-immu- 
nized C57BL/6J mice were roughly equivalent with respect to both the percentage of 
mononuclear leukocytes that bound IgG- or complement-coated erythrocytes and the 
total number of immune ligand-coated erythrocytes attached to each leukocyte. It is 
important  to  note,  however,  that  a  significantly smaller  percentage  of the  BCG- 
elicited adherent mononuclear cells ingested IgG or complement-coated erythrocytes 
than  did  the  adherent  cells  from  normal  mice,  and  each  of  these  BCG-elicited 
adherent cells ingested fewer immune ligand-coated erythrocytes than did its unstim- 
ulated counterpart. 
Resident macrophages from outbred Swiss mice (from The Rockefeller University, 
TABLE V 
Phagocytosis by C57BL/ 6J Adherent Cells 
Ingestion of E(IgG)*  Binding of E(IgG) 
Percent-  Percent- 
age of  Phago-  age of  Attach- 
macro-  macro-  Attach-  ment 
Phagocytic  cytic  in-  phages  ment  index: 
phages  index:]:  dex: con- 
with  with  index:~  percentage 
E(IgG)  trol  E(IgG)  of control 
ingested  attached 
Resident  88  630  100  74  1,192  100 
BCG elicited  57  242  38  79  1,192  100 
Ingestion of E(IgM)C'§  Binding of E(IgM)C' 
Resident  79  362  100  81  1,481  100 
BCG elicited  58  149  41  80  1,193  81 
Ingestion of IgG-GRBC 
Resident  95  2,184  100 
BCG elicited  96  1,378  64 
Ingestion of HRP-IgG 
Resident  92  NAIl 
BCG elicited  90  NA 
C57BL/6J  peritoneal cells, either BCG elicited or resident (unelicited), were plated on  13-mm glass 
coverslips at a density of 2 X 105-2.5 ×  105 cells per coverslip in MEM +  10% fetal bovine serum. The 
cells were allowed to adhere for 4 h at 37°t2, and then binding  and phagocytosis of IgG- or complement- 
coated erythrocytes or immune complexes was carried out as described in Materials and Methods. 
* E(IgG), IgG-eoated sheep erythrocytes. 
:~ Phagocytic and attachment indices were determined as described in Materials and Methods. 
§ E(IgM)C', complement-coated sheep erythrocytes. 
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New  York)  do  not  ingest  complement-coated  erythrocytes via  their  complement 
receptors (17,  18). The finding that complement receptors of resident macrophages 
from C57BL/6J mice promote phagocytosis of  these particles was therefore unexpected 
and requires additional investigation. 
To  further  explore  the  phagocytic  capacity  of BCG-elicited  adherent  cells,  we 
measured their ability to ingest IgG-coated glutaraldehyde-fixed sheep erythrocytes 
(IgG-GRBC)  or  horseradish  peroxidase-anti-horseradish  peroxidase  immune  com- 
plexes (HRP-IgG). In these experiments, 96% of the BCG-adherent cells ingested IgG- 
GRBC; similarly, 90% of these cells ingested the HRP-IgG immune complexes (Table 
V).  These results confirm that  between  90  and  95% of the  BCG-elicited adherent 
mononuclear cells bear Fc receptors and are phagocytic. We conclude, therefore, that 
nearly all of them are macrophages. 
The  experiments  described  thus  far  show  that  BCG-elicited  macrophages  are 
required to inhibit the grafting of the Bs59 melanoma; however, they do not indicate 
whether these macrophages act as cytotoxic effector cells or require, in addition, the 
ingress and participation of host leukocytes. To examine these questions, x-irradiated 
C57BL/6J or nude BALB/c mice were used as recipients of a mixture of BCG-elicited 
peritoneal cells and  melanoma cells.  Mice were irradiated with 650 tad  (Materials 
and Methods) 24-36 h before inoculation with the cell mixture. 
Mice irradiated with 650 rad have markedly decreased numbers of leukocytes in 
their  blood,  beginning  24-48  h  after  irradiation;  this  depression  in  circulating 
leukocytes lasts for 15-20 d  (19).  In studies to be reported in detail elsewhere (T. A. 
Calvelli, V. H. Freedman, S. Silagi, and S. C. Silverstein. Manuscript in preparation.) 
we  have  observed  that  a  variant  melanoma  cell  line  that  elicits  a  pronounced 
inflammatory response when inoculated subcutaneously into normal C57BL/6J mice, 
fails to evoke any infiltrations of  either polymorphonuclear or mononuclear leukocytes 
when injected into C57BL/6J mice previously irradiated with 650 rad. For this reason, 
we assume that C57BL/6J mice given 650 rad of total-body irradiation are incapable 
of mounting an inflammatory response to the tumor inoculum in the subcutaneous 
tissue. 
When mice irradiated 24-36 h  before were injected with BCG-elicited peritoneal 
cells admixed with Bs59 cells,  14 out of 16 animals had no evidence of tumor 51  d 
later (Table VI). Similarly, when the same experiments were carried out using nude 
mice as recipients, 11 out of 13 nude mice had no tumors 60 d after inoculation. In all 
cases, control animals given only the melanoma cells succumbed to the tumors (Table 
VI). These experiments show that immunologically impaired mice are protected from 
developing a  melanoma by the simultaneous administration of BCG-elicited perito- 
neal cells with the tumor cells. We conclude therefore that the BCG-elicited peritoneal 
cells themselves are capable of exerting a cytotoxic effect against the tumor cells, and 
that participation of host leukocytes is not required for the prevention of melanoma 
formation. 
The Bs59 cells used in these experiments do not elicit concomitant immunity. This 
was shown  in experiments in which a  total of 20 C57BL/6J mice were inoculated 
with 2 X  l0  s Bs59 cells in the left flank. All of these mice developed tumors with a 
latent period of 11.5 :l: 2.8 d.  13-19 d after the first inoculation (a time when tumors 
were already manifest) these mice were injected with 2 X l0  s Bs59 cells in the opposite V.  FREEDMAN,  T.  CALVELLI,  S.  SILAGI,  AND  S.  SILVERSTEIN  667 
TABLE  VI 
Effect of BCG-induced Peritoneal Exudate  Cells on Tumorigenicity ofB559 Cells in x-irradiated or Nude 
Mice 
No. mice with tumors/No, mice injected 
Cells injected  Irradiated*  Nude:l:  Normal§ 
Exp.  1  Exp. 2  Exp.  1  Exp. 2  Exp.  1  Exp. 2 
B559  8/8  5/5  3/4  3/3  4/4  6/6 
B559 +BCG-PEII  1/8  1/8  0/5  2/8  0/5  0/5 
* 6- to 8-wk-old  C57BL/6J female mice were exposed to 650 rad from a cesium gamma source.  24-36 h 
later, the mice were inoculated subcutaneously with either 2 ×  l0  s B559 cells or a mixture of 2 X 106 B559 
cells and 5 x  106 BeG-elicited peritoneal exudate cells (BCG-PE). Mice without gross evidence of tumors 
were killed and dissected 48 d after inoculation. 
~: 8- to 12-wk-old BALB/c nude mice were used. The experimental protocol was as described above except 
that the surviving mice were killed and dissected 54 d after inoculation. 
§ 6-  to 8-wk-old  C57BL/6J female mice were  used.  The experimental protocol was as described above 
except that the surviving mice were killed and dissected 60 d after inoculation. 
II Peritoneal exudate cells were elicited by immunizing C57BL/6J mice with heat-killed BCG as described 
in Materials and Methods and in Tables II-V. 
TAnLE  VII 
Injection of Bn59 Cells or Ba59 Cells Mixed with BCG-PE Cells Does Not Induce Immunity 
against the B559 Melanoma 
Latent period 
First inoculation*  Amputa-  Second  Mice with  after second 
tion:~  inoculation§  tumors  inoculation 
d 
B~59  Yes  None  0/811  -- 
B559  Yes  B559  8/8  12-14 
B559 +  BCG-PE  No  None  0/611  -- 
B559 +  BCGrPE  No  B559  6/6  12-14 
* C57BL/6J mice were injected subcutaneously in the thigh with 2 ×  105 B559 cells or subcutaneously 
in the flank with 2 ×  106 B559 cells and 5 ×  l0  s BCG-PE cells. 
1: After the tumors were palpable (8 d), the tumor-bearing leg was removed surgically. 
§ 2 ×  106 B559 cells were injected subcutaneously in the flank on the contralateral side 29 d after the 
first inoculation. 
II Control animals were followed  for 60 d. 
flank. Tumors  developed  at  the second inoculation site in all mice at least as rapidly 
(mean  latent period 9.6 +  2  d)  as at  the site of the initial tumor  challenge. 
To  confirm  that  B559  cells  are  not  immunogenic  and  cannot  be  employed  to 
immunize  mice against  this melanoma,  mice were  rechallenged  with B559 cells after 
surgical removal of a  well-developed  melanoma.  These mice developed  tumors  at the 
second inoculation site at approximately  the same rate as naive mice given a  primary 
injection of tumor  cells (Table VII). 
It was possible that the BCG-elicited peritoneal cells exerted an adjuvant  effect and 
promoted  immunity  to  B559  cells.  Were  this  to  occur,  the  immunity  evoked  could 
play  an  important  role  in  inhibiting  melanoma  formation  in  mice  inoculated  with 
BCG-elicited peritoneal  cells and  B559 cells. The  experiments  described  in Table  VI 
with  irradiated  or  nude  mice  as  recipients  suggested  that  this  does  not  occur. 
Nevertheless, we performed  the following experiment  to exclude this possibility. Mice 668  PREVENTION  OF  MELANOMA GRAFTS  BY  ACTIVATED  MACROPHAGES 
were inoculated with a  mixture of BCG-elicited peritoneal cells and B559 cells.  As 
expected, none of these mice developed tumors. 30 d after the first inoculation, these 
mice were rechallenged with B559 cells on the contralateral side. All of these animals 
developed melanomas with the same rapidity as the control mice (Table VII). Thus, 
the  prevention  of tumor  formation  by  the  concomitant  administration  of BCG- 
peritoneal cells and the Bs59 melanoma cells does not stimulate immunity to a second 
challenge with the B~59 cells. 
Discussion 
The potential importance of activated macrophages in tumor immunity has been 
recognized for nearly a decade. Scores of reports document the capacity of appropri- 
ately stimulated adherent cells to inhibit tumor cell growth, or to promote tumor lysis 
in cell culture systems (reviewed in 20, 21). However, comparatively few investigators 
have examined the effects of co-injection of immunologically activated peritoneal 
macrophages with syngeneie tumor cells on tumorigenesis in a syngeneic host animal 
(22-24).  Our study was undertaken to define optimal conditions for eliciting such 
activated cells, to assess the capacity of these cells to inhibit tumor formation by a 
well-characterized syngeneic tumor in vivo, and to evaluate the relative roles of naive 
host-derived  leukocytes and  of stimulated  donor-derived  leukocytes  in  inhibiting 
tumor formation in vivo. 
Systemic  infection  with  a  living  microorganism,  as  described  in  several  other 
investigations (1-7),  is not necessary to elicit protection against B16 melanoma. In 
fact, systemic infection may be counter-productive (Fig.  1). Systemic infection with 
BCG induces natural suppressor cells in the bone marrow and spleen (25, 26). These 
suppressor cells have been shown to inhibit cell-mediated immunity in vitro (26).  If 
a  similar mechanism exists in vivo, systemic infection with live BCG may promote 
inhibition of immune reactions  that  are  essential  for tumor  cell  eradication.  Our 
experiments indicate that local immunization with dead BCG, rather than systemic 
infection with  live  BCG,  is  a  more  successful adjuvant  for immunotherapy. This 
suggestion is  supported  by  reports  describing potent  anti-tumor effects after local 
administration of cell walls from either BCG or from Nocardia  rubra, a  Mycobacterium- 
related organism (22). 
Immunological cross-reactivity between BCG and a  human melanoma has been 
suggested as a mechanism for the tumor-inhibitory effects of BCG (27-29). Two lines 
of evidence indicate that such cross-reactivity is not responsible for the effects of BCG 
immunization reported here. First, peritoneal lymphocytes (nonadherent cells)  from 
BCG-immunized mice do not inhibit tumorigenesis by B16 melanoma cells (Table 
IV). These lymphocytes do respond to BCG antigens, however. This is indicated by 
our preliminary findings that  peritoneal  lymphocytes from BCG-immunized mice 
confer the capacity to resist challenge with B 16 melanoma cells upon naive mice when 
they are administered together with heat-killed BCG. Heat-killed BCG alone has no 
effect (V.  H.  Freedman and S.  C.  Silverstein. Unpublished observations.).  Second, 
intraperitoneal BCG immunization does not confer systemic immunity to B I6 mela- 
noma cells. Mice challenged subcutaneously, that is, at a site distant from the original 
immunization(s), develop melanomas (Table II). In addition, mice inoculated with 
mixtures of BCG-elicited peritoneal cells (containing BCG) and B559 tumor cells, are 
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Systemic immunity to B16 melanoma cells can be elicited by immunizing C57BL/ 
6J mice with a nontumorigenic variant of this tumor (30). Thus when a suitable cross- 
reacting antigen is used  for immunization, systemic immunity to B16 melanoma is 
observed. We conclude that  immunological cross-reactivity between BCG and  B16 
melanoma cells is not responsible for the inhibitory effects of BCG-elicited peritoneal 
cells or for tumorigenesis by B16 melanoma. 
The nature of the cytotoxic cells in the BCG-elicited peritoneal exudate has been 
explored. The effector cells are concentrated exclusively in the adherent cell fraction 
(Table IV). At least 90% of these adherent cells possess Fc receptors (as measured by 
their uptake of HRP-IgG), and >95% of them are phagocytic (as measured by their 
injection of IgG-GRBC). Their phagocytic capacity distinguishes the vast majority of 
these cells from the nonphagocytic adherent cell described by Nathan et al.  (31) and 
identifies them as mononuclear phagocytes. However, mononuclear phagocytes elic- 
ited by immunization with heat-killed BCG, and maintained in vitro for 4 h differ in 
several respects from resident macrophages or from macrophages induced by other 
inflammatory stimuli  (18,  32). They ingest fewer erythrocytes than their resident or 
inflammatory counterparts (Table V;  and  [31]),  and they exhibit a  lower pinocytic 
rate  2 than either resident or inflammatory macrophages (V. H. Freedman and S. C. 
Silverstein. Unpublished observations.). 
BCG elicits natural killer cells (34) and it has been suggested that this cell may be 
responsible  for the  in  vitro  tumoricidal  activity of BCG-elicited  mononuclear cell 
preparations.  Most investigators report that  both murine and human  natural killer 
cells  are  neither  adherent  nor  phagocytic  (35-37);  the  effector cells  used  in  our 
experiments are adherent and >90% of them are phagocytic. Thus is seems unlikely 
that  natural  killer  cells  make  a  significant  contribution  to  the  tumor-inhibitory 
properties of mononuclear phagocytes elicited with heat-killed BCG. 
However, there may be a relationship between natural killer cells and mononuclear 
phagocytes. Reinherz et al. (38) have shown that human mononuclear cell populations 
that  express  natural  killer  activity  contain  a  surface  antigen  that  is  present  on 
monocytes and granulocytes. They suggest that human natural killer cells are members 
of the monocyte-myeloid series. 
Our experiments show that mononuclear phagocytes elicited by two immunizations 
with  heat-killed  BCG  prevent  tumorigenesis  by  B16  melanoma  cells  in  syngeneic 
C57BL/6J mice. They suggest  that  these cells eradicate B16 melanoma cells in the 
absence of additional participation by host leukocytes. This was tested by inoculating 
nude or sublethally irradiated (650 rad) recipient mice with mixtures of BCG-immune 
peritoneal cells and melanoma cells (Table VI). 84% of the nude mice and 87% of the 
irradiated mice were protected from tumor formation by the BCG-immune peritoneal 
cells.  However, 100% of the control mice were protected from tumor formation by the 
BCG-immune peritoneal cells.  Thus it is possible that  host-derived leukocytes may 
play some role in the permanent eradication of the melanoma graft. 
Despite the presence in their peritoneal cavities of cells capable of destroying the 
tumor inoculum, BCG-immunized B57BL/6J mice are not protected from melanoma 
formation  when  injected  with  this  tumor  subcutaneously.  This  could  occur  as  a 
2 Edelson and Erbs (33) reported that BCG-elicited maerophages have an enhanced pinocytic rate. The 
cells  used in their study differed  from those used here because the cells  used by Edelson and  Erbs were 
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consequence of at  least  two separate  processes.  First,  blood monocytes from BCG- 
immunized  mice may not  be capable of inhibiting tumorigenesis when co-injected 
with  B16  melanoma  cells  into  naive  C57BL/6J  mice.  Monocytes  may  develop 
tumoricidal  capacity only after  their emigration  from  the  vascular  compartment. 
Second,  Synderman  and  Pike  (39)  have  documented  the  formation by  tumors  of 
inhibitors of monocyte chemotaxis in vitro. Histological studies of the early stages of 
melanoma development in naive or BCG-immunized mice show that there are very 
few host leukocytes in the melanoma before its vascularization (T. A. Calvelli, V. H. 
Freedman, S.  Silagi, and S. C. Silverstein. Manuscript  in preparation.). Thus mela- 
noma  cells  may  fail  to  promote  inhibit  leukocyte  emigration  from  the  vascular 
compartment into the tumor bed. 
However, within the peritoneal cavity, the interaction of BCG with BCG-sensitive 
T-lymphocytes promotes the  formation of lymphokines. These lymphokines act  as 
chemoattractants for the influx of blood monocytes (40) and as signals for monocyte 
differentiation (41, 42). Monocytes may therefore differentiate into cytotoxic effector 
cells only after they have emigrated from the blood into the tissues, and only when 
they  are  in  proximity with  antigen  driven  T-lymphocytes within  the  same  tissue 
compartment.  These cytotoxic macrophages  lack  the  capacity to  migrate  to  other 
tissues, but once implanted within the substance of a tumor, they destroy the tumor 
cells with which they are in contact. Hibbs (43, 44) has come to a similar conclusion 
from his studies of mice immunized with live toxoplasma or BCG. 
Summary 
We have demonstrated that a  murine cytotoxic peritoneal cell can be elicited by 
intraperitoneal  immunization  with  heat-killed  Mycobacterium  boris,  strain  Bacillus 
Calmette-Gu~rin  (BCG). When these cells are  injected together with cells of clone 
B559 of B 16 melanoma in a Winn-type transfer assay into syngeneic C57BL/6J mice, 
the tumorigenic potential of the melanoma is completely abrogated. Similarly, mice 
immunized  intraperitoneally with  dead  BCG are  protected against  intraperitoneal 
challenge with a number of B16 melanoma cells sufficient to cause tumors in 100% of 
control mice. However, mice immunized intraperitoneally with dead BCG are not 
protected against  tumor formation when B16 melanoma cells are injected subcuta- 
neously. Co-injection of BCG-elicited peritoneal cells with B 16 melanoma cells into 
nude or sublethally irradiated  (650 rad)  mice inhibits tumor formation in >85% of 
the mice, indicating that additional participation of host bone marrow- or thymus- 
derived leukocytes is not required to eradicate the tumor implant. The effector cell in 
the BCG-induced peritoneal exudate is adherent and phagocytic and is a mononuclear 
phagocyte.  Nonadherent  lymphoid  cells  from  the  same  BCG-induced  peritoneal 
exudate and from thioglycollate-broth-elicited granulocytes and macrophages neither 
prevent nor delay B16 tumor formation. 
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